Navigation Links
Transgenomic Reports First Quarter Financial Results
Date:5/12/2011

lar diagnostics laboratory market through our acquisition of the FAMILION laboratory testing business.  This acquisition brings us historic annual revenues of approximately $13.0 million and a much larger presence both with insurers and patients. This acquisition also provides us access to higher throughput technologies and an expert staff to aid us as we continue growing our reference laboratory business as well as consolidation opportunities already achieved in laboratory operations, billing and customer service functions.

In our Pharmacogenomic Services Lab, we continue to perform cancer pathway gene mutation analysis for a number of high visibility pharmaceutical companies both for pre-clinical drug discovery projects and phase II and III clinical trials.  Employing our recently licensed ultra sensitive DNA mutation detection technology, termed COLD-PCR, and a significant improvement to COLD-PCR termed Ice COLD-PCR; we can now analyze blood serum for DNA mutations rather than just testing patients' tumors. This is a significant achievement and should, we believe, lead to much faster expansion of our service testing for pharmaceutical partners as they adopt this novel approach for both drug and disease research.

In addition to Ice COLD-PCR, which offers sensitivity improvements as much as 1,000 times higher than routine DNA testing technology, we have recently discovered a technique to further improve mutation detection sensitivity of standard Sanger sequencing. We have termed this new discovery BLOCker-Sequencing and we are combining this new discovery with our Ice COLD-PCR program to bring what we believe to be the most accurate and sensitive mutation detection technology available in the market today. We believe that this combination of technologies offers us the ability to develop tests for cancer detection or to measure cancer recurrence at earlier stages in the disease process aiding in drug selection or drug resistance determinati
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Transgenomic Reports Fourth Quarter Financial Results
10. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
11. Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... - Broadened Diagnostic Criteria and Growing ... despite Patent Expirations ... Therapeutics to 2020 - Broadened Diagnostic ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... April 15, 2011 HeartWare International, Inc. (NASDAQ: ... innovator of less invasive, miniaturized circulatory support technologies ... failure, today announced the presentation of updated data ... study, ADVANCE, showing 180-day survival, using Kaplan-Meier analysis, ...
... Md., April 15, 2011 The U.S. Food and ... device to treat adults with glioblastoma multiforme (GBM) that ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the brain tissue. According to the National Cancer Institute, ...
Cached Medicine Technology:HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5FDA Approves New Medical Device for Form of Brain Cancer 2FDA Approves New Medical Device for Form of Brain Cancer 3
(Date:8/28/2014)... Career Step, an online provider of ... video designed to help students and career seekers explore ... field. The video details what medical coders and billers ... and the education requirements for entering this field. , ... overlooked when people are considering a career in healthcare,” ...
(Date:8/28/2014)... (PRWEB) August 29, 2014 VPS ... a physical server computer into many servers, each ... running on someone’s own dedicated computer. Top10BestSEOHosting.com has ... announces that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ), Bluehost and ... suppliers in 2014. , The IT manager of ...
(Date:8/28/2014)... AltMed , a fully ... to the development and production of medical cannabis, ... location in Sarasota County. , "Sarasota County ... commitment to attracting new industry and the job ... Wright, President and CEO of AltMed. "Their responsive ...
(Date:8/28/2014)... Fifty percent of adults who seek medical ... percent of Americans claim to have fatigue that is ... Fatigue is the most common yet overlooked cause of ... symptoms. Tasks that were once a breeze are now ... cause irritation, experiencing weight gain around the middle area ...
(Date:8/28/2014)... August 28, 2014 When David Gergen, ... long-time friend of Mark Brnovich, was asked to publicly ... nomination for the Attorney General seat in the State ... gathered the support of Cardinal Hall of Fame wide ... Derek Kennard and Mark Walczak. Green, Kennard and Walczak ...
Breaking Medicine News(10 mins):Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Top10BestSEOHosting.com Announces The Best Three VPS Hosting Suppliers 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Peoria AlignLife Clinics Focus on Community Education 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3
... paying fatally to keep thin, the Indian fashion fraternity says ... sari or the lehenga and the// models must keep healthy. ... say, and, are away from harm's way. ,The ... to anorexia, an eating disorder, and 22-year-old Luisel Ramos because ...
... prevent breast cancer and also help those who are suffering ... surveyed 15,000 women and found that those who indulged in ... no family history of breast cancer may be 23 percent ... exercise at all. ,Another study showed that a ...
... success in a Brazilian soap opera has inspired the production ... ,The doll will be based on "Paginas da ... Joana Mocarzel. ,In the soap, the five-year-old Clarinha ... Mocarzel's charisma combined with Brazilians' craze for soaps to make ...
... a million children in India suffering from serious hearing problems ... prohibitive cost of such surgery is keeping them away, health ... India suffer some kind of hearing problems and about a ... surgery. But the high cost of the device is proving ...
... plan to distribute 250,000 city-branded condoms as part of ... of HIV// and other sexually transmitted infections, the Washington ... yellow package is printed in English and Spanish and ... to stop HIV in D.C.' The first batch of ...
... at the University of Illinois at Urbana-Champaign have developed ... with sensitivity that rivals the performance of much more ... a fast, on-site test for assessing uranium contamination in ... Yi Lu, a chemistry professor at Illinois and senior ...
Cached Medicine News:Health News:Indian Models are a Healthy Lot 2Health News:Need for Cost-effective Hearing Implants 2Health News:Free Condoms Distribution to Prevent HIV in Washington 2Health News:DNA-based Detection of Heavy Metals 2
... Our Buffered Wright-Giemsa Stain is ... contains the fixative, buffer, and ... staining of blood smears. It ... bottle for ease of use ...
... Giemsa stain is an excellent classical ... blood smears and bone marrow. Erythrocytes ... exhibiting a very light, pale pink. ... cytoplasm stains the classical "ground glass" ...
Albumin (BCP). Storage temp: 15 - 30 C. Linearity: 0.5 - 8.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 250 number of tests....
Albumin reagent is used for the quantitative determination of albumin concentration in human serum....
Medicine Products: